ArticleScientific reports2018
Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Emerging roles of non-coding RNA derived from extracellular vesicles in regulating PD-1/PD-L1 pathway: insights into cancer immunotherapy and clinical applications.Cancer cell international · 2025Review
- GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2024Review
- Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.Frontiers in cell and developmental biology · 2024Review
- Employing CRISPR-Cas9 to Enhance T Cell Effector Function.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Expanded Alternatives of CRISPR-Cas9 Applications in Immunotherapy of Colorectal Cancer.Molecular diagnosis & therapy · 2024Review
- Review
- Knowledge mapping and current trends of global research on CRISPR in the field of cancer.Frontiers in cell and developmental biology · 2023Article
- Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.Molecular cancer · 2022Review
- The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle?Biomedicines · 2022Review
- Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.Frontiers in immunology · 2022Review
- HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy.Scientific reports · 2021Article
- Harnessing the Immune System to Fight Multiple Myeloma.Cancers · 2021Review
- CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2021Review
- Review
- Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.Cancer discovery · 2021Review
- CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.Frontiers in cell and developmental biology · 2021Review
- Future of CAR T cells in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2020Review
- Self-Maintaining CD103Cancer immunology research · 2020Article
- Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.Journal for immunotherapy of cancer · 2020Article
- TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
T cell function can be compromised during chronic infections or through continuous exposure to tumor antigens by the action of immune checkpoint receptors, such as programmed cell death protein 1 (PD-1). Systemic administration of blocking antibodies against the PD-1 pathway can restore T cell function, and has been approved for the treatment of several malignancies, although there is a risk of adverse immune-related side-effects. We have developed a method for generating gene knockouts in human antigen (Ag)-specific cytotoxic T-Lymphocyte (CTLs) using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing. Using this method, we generated several transduced CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.